AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in clinical trials and real-world studies. We characterized CD4+ and CD8+ T cell responses induced by AZD1222 vaccination in p...

Full description

Bibliographic Details
Main Authors:	Swanson, PA, Padilla, M, Hoyland, W, McGlinchey, K, Fields, PA, Bibi, S, Faust, SN, McDermott, AB, Snape, MD, Voysey, M, Lambe, T, Pollard, AJ, Durham, NM, Kelly, EJ, Adlou, S, Aley, PK, Angus, B, Anslow, R, Baker, P, Bansal, H, Beveridge, A, Bridges-Webb, A, Ching, S, Cicconi, P, Clutterbuck, EA, Collins, AM, Darton, TC, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Ewer, KJ, Felle, S, Ferreira, DM, Folegatti, PM, Fuskova, M, Gaudinski, M, Gilbert, SC, Goodman, AL, Gordon, I, Green, CA, Harbolick, E, Hayes, S, Hill, AVS, Hill, H, Jenkin, D, Jepson, BM, Kasanyinga, M, Libri, V, Lillie, PJ, McGregor, AC
Other Authors:	AstraZeneca/Oxford/VRC Study Group
Format:	Journal article
Language:	English
Published:	American Association for the Advancement of Science 2021

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.

Similar Items